Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Abbott 3Q11

Pharmaceuticals sales up 14%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 3Q11

3Q Revenues: $9.8 billion (+13%)

3Q Earnings: $303 million (-66%)

YTD Revenues: $28.5 billion (+13%)

YTD Earnings: $3.1 billion (+2%)

Comments: Pharmaceuticals sales were up 14% in the quarter to $4.3 billion.
Humira sales were up 26% to $2.1 billion. Kaletra sales were down 9% to $297.0 million. TRILIPIX/TriCor sales were up 2% to $419.0 million. Emerging markets sales were $2.6 billion, up 21%. Earnings in the quarter include a $1.5 billion pre-tax reserve for litigation related to Depakote. R&D expenses were $1.0 billion in the quarter, down 6%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters